Ligand (LGND) Breakout! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout!

LGND 184.82

-2.0%

Dec 5 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Andrew H who wrote (16442)	3/4/1998 4:10:00 PM
From: Henry Niman	Read Replies (1) of 32384

Andrew, The function of a P3 is to provide sufficient numbers of patients at the optimal concentration to prove efficacy and safety. LGND's compounds' effects are robust. The International Phase III trial (topical Panretin) was supposed to test about 270 patients. Instead it was halted at about 115 because the data was so strong. Now oral Panretin has produced at 37% and 38% response rate in two totally separate Phase II trials (one by LGND and one by the AIDS Consortium), so they could be considered the equivalent of a halted Phase III trial. LGND will present a bit more in the next few months (and as you know, the longer the patient population is on the drug, the better the data gets), and it's really the same drug for the same disease (only the formulation has change), with similar data (about 40% respond), so it's not that hard to make a convincing argument that the drug is safe and effective in oral and topical formulations.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next